Clinical implications of FLT3 mutations in pediatric AML.
about
Structural and functional alterations of FLT3 in acute myeloid leukemiaPrevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaOptimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaEmergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.The role of tumor microenvironment in therapeutic resistanceRUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case reportImpact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology GroupCurrent Management of Childhood Acute Myeloid Leukemia.Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in KoreaIndoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AMLHypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaPrevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemiaGemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.The Biology and Targeting of FLT3 in Pediatric Leukemia.NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence dataThe multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology GroupFLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Novel agents for the treatment of childhood acute leukemia.Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.Who is fit for allogeneic transplantation?Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.The incidence and clinical significance of nucleophosmin mutations in childhood AML.
P2860
Q24338964-466AE4AD-F60F-43CD-BC67-548C5E425DC0Q24602856-48246A5A-52D3-4F5E-84FB-821DCBDAE4D5Q26992280-76319D38-48C5-422E-B9E5-5AA2FB186971Q27005960-A684DB66-5F26-46AB-A263-E4CF4F9D7712Q27674324-8A8F1197-F82F-45A4-B2CB-B75AA282C7EBQ27852520-631E8FC2-10D8-4B57-AA05-340CE89509ABQ28069049-5D76F3DF-93FF-4ABD-83E8-FF5CA02064E3Q28597831-C5267AA5-B065-4914-B473-47F7AE550458Q28755379-D07F58CD-7808-40C1-A207-E41C22233A60Q30244036-B42EBBB7-6C6B-4B00-A91D-AB41A3AB552CQ33565514-30ED7EB8-302F-4E61-AD3D-265BEFD7080FQ33688517-0AF10011-AC62-445C-B833-F76B2AAB129FQ33702150-CBA26FDE-4D85-4D34-A999-C8E4685954C9Q33729914-8B057AFF-8B95-401B-91E5-BE83E60DEF51Q33754603-656FB28D-FE66-4F09-A43D-74B339081A25Q33774504-015D9D3B-1FA9-45A2-A6B4-1154153E2F1AQ33838668-FBDAA607-EED8-456F-A896-9505EEB72CA6Q33872395-E1E13CFE-25DC-4CF0-9693-2FE3F4D1AAD5Q33913329-C781093A-099B-4DDB-84D5-444820AC6348Q34052581-7F652785-3777-4E24-8F77-0F46F3EEFA64Q34154213-126614DF-A8CC-4650-969F-9DC4BCD1A35AQ34172042-9492ED58-457D-49FA-BDEF-C3466149B61DQ34229555-D46569D6-5F0B-4481-9E20-60E0E9C1491EQ34318490-23B22DAE-9B31-49C0-8F93-503356D76D16Q34647741-2B2A1313-9E74-4F76-8092-F9822C06768BQ34754867-674385EC-678A-4AD9-B794-B39953A4EB6CQ34764504-865AF180-86C6-454D-955B-3EB573892871Q34845224-A324766C-C470-446B-A85D-7331A6944A5FQ35037810-15109181-9693-4209-BEE7-EA50CA10C6EBQ35038725-EF35D28F-EAA0-4CC7-9583-173558213CFEQ35046171-49846422-DDEC-4957-AA50-EBDE81D07145Q35048217-3DD5B792-8A44-4EAB-A983-6CF7E5E830FDQ35192790-5138DEAC-F8D1-4292-822E-5EDD7965ED5AQ35215042-1FF03975-BBAC-4628-9151-18790D78DF2FQ35430146-0D5E764A-DA62-445D-881F-02CB05BE6160Q35660739-40135CBD-6E97-4D06-93D1-5CBBF9F04872Q35740058-F372A07B-33E3-4442-844D-4F09BCE44700Q35848149-926AF984-0536-48FC-8B67-63B4633BC487Q35849209-7B7C8432-AAB9-45B8-891B-91D6AEDE18B4Q35901721-61147D19-FD74-47F5-8723-8BF5D1ECA912
P2860
Clinical implications of FLT3 mutations in pediatric AML.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Clinical implications of FLT3 mutations in pediatric AML.
@ast
Clinical implications of FLT3 mutations in pediatric AML.
@en
type
label
Clinical implications of FLT3 mutations in pediatric AML.
@ast
Clinical implications of FLT3 mutations in pediatric AML.
@en
prefLabel
Clinical implications of FLT3 mutations in pediatric AML.
@ast
Clinical implications of FLT3 mutations in pediatric AML.
@en
P2093
P2860
P1433
P1476
Clinical implications of FLT3 mutations in pediatric AML.
@en
P2093
Beverly J Lange
Derek L Stirewalt
Dirk Reinhardt
Gertjan J L Kaspers
Jerald P Radich
Martin Zimmerman
Michel Zwaan
Robert Gerbing
Soheil Meshinchi
Todd A Alonzo
P2860
P304
P356
10.1182/BLOOD-2006-03-009233
P407
P577
2006-08-15T00:00:00Z